Application of allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia in the era of targeted therapy / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 11-15, 2022.
Article
em Zh
| WPRIM
| ID: wpr-929724
Biblioteca responsável:
WPRO
ABSTRACT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the main curable therapies for patients with acute lymphoblastic leukemia (ALL). This article discusses the status of allo-HSCT for ALL as well as how to combine targeted therapy with allo-HSCT to improve outcomes of ALL in the era of targeted therapy based on the data obtained from the 63rd American Society of Hematology (ASH) Annual Meeting.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2022
Tipo de documento:
Article